Overview

Safety and Efficacy of BC LisPram

Status:
Not yet recruiting

Trial end date:
2022-01-01

Target enrollment:

Participant gender:

Summary

This pilot study is a 50-hour randomized, open-label, crossover study in an inpatient setting assessing the safety, pharmacodynamics, pharmacokinetics, and closed-loop efficacy of i) BC LisPram delivery and ii) rapid insulin delivery.

Phase:

Phase 1

Details

Lead Sponsor:

Michael Tsoukas

Collaborator:

Adocia

Treatments:

Insulin Lispro